| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Sign In to gain access to subscriptions and/or personal tools.
|
|
|
|||||||
Sign In to gain access to subscriptions and/or personal tools. |
|||||||||
Articles |
AmBisome (NeXstarPharmaceuticals, San Dimas, CA) is a unilamellar liposomal formulation of amphotericin B that was recently approved for use as empirical treatment for presumed fungal infections in febrile neutropenic patients and for aspergillosis, candidiasis, and cryptococcosis infections refractory to amphotericin B. It is a small closed microscopic sphere (<100 nm in diameter) with an inner aqueous core (i.e., a true liposome). AmBisome remains as an intact sphere in vitro and for prolonged periods of time in vivo during the processes of systemic transport and pharmacologic action. As a consequence of its size and in vivo stability, AmBisome has physiochemical properties and a pharmacokinetic profile that are considerably different from those of currently available lipid-complexed amphotericin B formulations, with greatly increased area under the plasma concentration-time curve and much lower clearance at equivalent doses. AmBisome liposomes can be seen to accumulate at sites of fungal infection. Disruption of AmBisome liposomes occurs after attachment to the fungal cell wall and results in amphotericin B binding to fungal cell membrane ergosterol with subsequent cell lysis. AmBisome has been shown to penetrate the cell wall of both extracellular and intracellular forms of susceptible fungi.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati 
Twitter What's this?
This article has been cited by other articles:
|
|
 |
|
  J. A. Olson, J. P. Adler-Moore, G. M. Jensen, J. Schwartz, M. C. Dignani, and R. T. Proffitt Comparison of the Physicochemical, Antifungal, and Toxic Properties of Two Liposomal Amphotericin B Products Antimicrob. Agents Chemother., January 1, 2008; 52(1): 259 - 268. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Smith, J. A. Olson, D. Constable, J. Schwartz, R. T. Proffitt, and J. P. Adler-Moore Effects of dosing regimen on accumulation, retention and prophylactic efficacy of liposomal amphotericin B J. Antimicrob. Chemother., May 1, 2007; 59(5): 941 - 951. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Olson, J. P. Adler-Moore, J. Schwartz, G. M. Jensen, and R. T. Proffitt Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model. Antimicrob. Agents Chemother., June 1, 2006; 50(6): 2122 - 2131. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Vogelsinger, S. Weiler, A. Djanani, J. Kountchev, R. Bellmann-Weiler, C. J. Wiedermann, and R. Bellmann Amphotericin B tissue distribution in autopsy material after treatment with liposomal amphotericin B and amphotericin B colloidal dispersion J. Antimicrob. Chemother., June 1, 2006; 57(6): 1153 - 1160. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Takemoto, Y. Yamamoto, Y. Ueda, Y. Sumita, K. Yoshida, and Y. Niki Comparative study on the efficacy of AmBisome and Fungizone in a mouse model of pulmonary aspergillosis J. Antimicrob. Chemother., April 1, 2006; 57(4): 724 - 731. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Hong, P. J. Shaw, C. E. Nath, S. P. Yadav, K. R. Stephen, J. W. Earl, and A. J. McLachlan Population Pharmacokinetics of Liposomal Amphotericin B in Pediatric Patients with Malignant Diseases Antimicrob. Agents Chemother., March 1, 2006; 50(3): 935 - 942. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. N. Oda, P. L. Hargreaves, J. A. Beckstead, K. A. Redmond, R. van Antwerpen, and R. O. Ryan Reconstituted high density lipoprotein enriched with the polyene antibiotic amphotericin B J. Lipid Res., February 1, 2006; 47(2): 260 - 267. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Adler-Moore, J. A. Olson, and R. T. Proffitt Alternative dosing regimens of liposomal amphotericin B (AmBisome) effective in treating murine systemic candidiasis J. Antimicrob. Chemother., December 1, 2004; 54(6): 1096 - 1102. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Takemoto, Y. Yamamoto, Y. Ueda, Y. Sumita, K. Yoshida, and Y. Niki Comparative studies on the efficacy of AmBisome and Fungizone in a mouse model of disseminated aspergillosis J. Antimicrob. Chemother., February 1, 2004; 53(2): 311 - 317. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Laguna, S. Videla, M. E. Jimenez-Mejias, G. Sirera, J. Torre-Cisneros, E. Ribera, D. Prados, B. Clotet, M. Sust, R. Lopez-Velez, et al. Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study J. Antimicrob. Chemother., September 1, 2003; 52(3): 464 - 468. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Bellmann, P. Egger, W. Gritsch, R. Bellmann-Weiler, M. Joannidis, N. Kaneider, S. Dunzendorfer, and C. J. Wiedermann Amphotericin B lipid formulations in critically ill patients on continuous veno-venous haemofiltration J. Antimicrob. Chemother., March 1, 2003; 51(3): 671 - 681. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Gerbaud, F. Tamion, C. Girault, K. Clabault, S. Lepretre, J. Leroy, and G. Bonmarchand Persistent acute tubular toxicity after switch from conventional amphotericin B to liposomal amphotericin B (Ambisome) J. Antimicrob. Chemother., February 1, 2003; 51(2): 473 - 475. [Full Text] [PDF]
|
|
|
|
 |
|
 P. C. Johnson, L. J. Wheat, G. A. Cloud, M. Goldman, D. Lancaster, D. M. Bamberger, W. G. Powderly, R. Hafner, C. A. Kauffman, W. E. Dismukes, et al. Safety and Efficacy of Liposomal Amphotericin B Compared with Conventional Amphotericin B for Induction Therapy of Histoplasmosis in Patients with AIDS Ann Intern Med, July 16, 2002; 137(2): 105 - 109. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Bekersky, R. M. Fielding, D. E. Dressler, J. W. Lee, D. N. Buell, and T. J. Walsh Pharmacokinetics, Excretion, and Mass Balance of Liposomal Amphotericin B (AmBisome) and Amphotericin B Deoxycholate in Humans Antimicrob. Agents Chemother., March 1, 2002; 46(3): 828 - 833. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Bekersky, R. M. Fielding, D. E. Dressler, J. W. Lee, D. N. Buell, and T. J. Walsh Plasma Protein Binding of Amphotericin B and Pharmacokinetics of Bound versus Unbound Amphotericin B after Administration of Intravenous Liposomal Amphotericin B (AmBisome) and Amphotericin B Deoxycholate Antimicrob. Agents Chemother., March 1, 2002; 46(3): 834 - 840. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Sulis, C. Van de Ven, T. Henderson, L. Anderson, and M. S. Cairo Liposomal amphotericin B (AmBisome) compared with amphotericin B {+/-} FMLP induces significantly less in vitro neutrophil aggregation with granulocyte-colony-stimulating factor/dexamethasone-mobilized allogeneic donor neutrophils Blood, January 1, 2002; 99(1): 384 - 386. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. W. Townsend, A. Zutshi, and I. Bekersky Biodistribution of 4-[14C]Cholesterol-AmBisome following a Single Intravenous Administration to Rats Drug Metab. Dispos., April 13, 2001; 29(5): 681 - 685. [Abstract] [Full Text]
|
|
|
|
 |
|
 E. Bennett-Guerrero, T. J. McIntosh, G. R. Barclay, D. S. Snyder, R. J. Gibbs, M. G. Mythen, and I. R. Poxton Preparation and Preclinical Evaluation of a Novel Liposomal Complete-Core Lipopolysaccharide Vaccine Infect. Immun., November 1, 2000; 68(11): 6202 - 6208. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Machard, F. Theodoro, H. Benech, J.-M. Grognet, and E. Ezan A Sensitive Amphotericin B Immunoassay for Pharmacokinetic and Distribution Studies Antimicrob. Agents Chemother., March 1, 2000; 44(3): 546 - 550. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
